Physician profile
Robert J Melfi
NPI 1346213998
$3,987.59
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,652 · 2020: $289 · 2021: $46.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $3,073.56 | 2019 | |
| Novo Nordisk INC | $519.87 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $73.52 | 2019-2020 | |
| Medtronic Minimed, INC. | $62.19 | 2019 | |
| Insulet Corporation | $43.27 | 2019 | |
| Mannkind Corporation | $30.26 | 2020 | |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Amarin Pharma, INC. | $24.12 | 2019 | |
| Abbott Laboratories | $21.79 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.60 | 2019 | |
| Becton, Dickinson and Company | $17.68 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.37 | 2021 | |
| Clarus Therapeutics INC. | $15.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2019 | |
| Lilly USA, LLC | $14.23 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Melfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.